TachoSil®

Product description: TachoSil® (surgical patch) combines the bioactive mechanism of action of human coagulation factors, fibrinogen and thrombin, with the mechanical support of a collagen patch. TachoSil® is approved for haemostasis (control of bleeding), and for sealing of tissues in surgery. Upon contact with blood or other fluids, the coagulation factors react to form a fibrin clot that sticks TachoSil® to the tissue surface, producing an air- and liquid-tight seal in three to five minutes. TachoSil® was launched in 2004 and is available in more than 30 countries. In April 2010, Tachosil® was approved by the US Food and Drug Administration. In the United States, TachoSil® will be launched by Nycomed’s distribution and marketing partner Baxter International.

Medical need: The TachoSil® patch meets a critical need that  surgeons have in achieving fast and reliable haemostasis and sealing of soft tissues. It provides protection against post-operative re-bleedings and leaks that can lead to re-operations and extended hospital stays. Furthermore, it eliminates the need for surgical removal because it is made from collagen, a substance that is naturally absorbed by the body.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.